Atlas Trials

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Clinical trial NCT07011056 · RECRUITING

Trial details

NCT number
NCT07011056
Sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Recurrent and Refractory Diffuse Large B-cell Lymphoma
Start date
2025-07-18
Primary completion
2029-06-30
Enrollment
390

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.